GSK-Enigma flu test deal
This article was originally published in The Gray Sheet
Executive Summary
GlaxoSmithKline and Salisbury, U.K.-based Enigma Diagnostics are partnering to supply the first point-of-care influenza tests to identify specific flu virus strains, the firms announce July 21. The tests, based on the Enigma ML (mini laboratory) real-time polymerase chain reaction technology platform, will provide fully-automated results from swab samples in less than an hour, with the same accuracy standards as reference laboratory tests that take several days, according to GSK. A European trial of working prototypes of the Enigma ML tests will begin in the fourth quarter of this year, according to the company